Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix (Nasdaq: NRIX) reported Q4 and FY2025 results and operational milestones on January 28, 2026. Key clinical advances include an 83% ORR and median PFS 22.1 months for bexobrutideg in relapsed/refractory CLL and initiation of the DAYBreak™ pivotal Phase 2 program at 600 mg once daily. Corporate actions include a $250.0 million registered offering and cash and marketable securities of $592.9 million as of Nov 30, 2025.
FY2025 revenue was $84.0 million; R&D expense rose to $316.9 million and net loss was $264.5 million.
Nurix (NASDAQ: NRIX) outlined 2026 objectives to advance its BTK degrader bexobrutideg through pivotal development in relapsed/refractory CLL, including the ongoing Phase 2 DAYBreak CLL-201 (600 mg once daily) and a planned confirmatory Phase 3, DAYBreak CLL-306, versus pirtobrutinib. Clinical updates reported an 83% objective response rate and median progression-free survival of 22.1 months in heavily pretreated CLL cohorts. Nurix is also testing a tablet formulation to support INDs in autoimmune/inflammatory indications in 2026, advancing partnered degrader programs (IRAK4 with Gilead; STAT6 with Sanofi), and reported pro forma cash/investments of $663.8M after a $250M registered offering in Oct 2025.
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., president and CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 4:30 p.m. PT in San Francisco.
The presentation will be webcast live and accessible via a link in the Investors section of the Nurix website, with the archived webcast available for 30 days after the event.
Nurix Therapeutics (Nasdaq: NRIX) presented Phase 1 data for BTK degrader bexobrutideg (NX-5948) in relapsed/refractory Waldenström macroglobulinemia at ASH on December 8, 2025.
In 31 treated patients (median age 71), 28 were evaluable and achieved an objective response rate (ORR) of 75.0% (VGPR 10.7%, PR 50.0%, MR 14.3%). Median follow-up was 8.1 months; median duration of response and median progression-free survival were not reached. Responses occurred regardless of MYD88/CXCR4 status, and 14 patients remained on treatment >6 months.
Safety was manageable: common AEs included neutropenia 29.0% and diarrhea 25.8%; no dose-limiting toxicities or grade 5 AEs were observed.
Nurix (NASDAQ: NRIX) reported updated Phase 1a/1b data for bexobrutideg (NX-5948) in relapsed/refractory CLL/SLL presented at ASH 2025.
Key clinical metrics: ORR 83% (Phase 1a, n=47 evaluable) including 2 complete responses, median PFS 22.1 months, median DOR 20.1 months, and a DCR of 95.7%. Randomized Phase 1b cohort (200 mg vs 600 mg, n=42) showed higher ORR at 600 mg: 83.3% vs 73.7% and a trend toward longer PFS; 600 mg was selected as the RP2D. Safety was consistent across doses (n=126 overall; n=70 at 600 mg) with common TEAEs including purpura/contusion, neutropenia, and petechiae; no dose-limiting toxicities, no systemic fungal infections, and no Grade 4 infections reported.
DAYBreak-CLL-201 Phase 2 is enrolling globally; a company webcast is scheduled for Dec 8, 2025, 8:15 p.m. ET.
Nurix Therapeutics (Nasdaq: NRIX) will host a live webcast on Monday, December 8, 2025 at 8:15 p.m. ET to review new and updated clinical data from the ongoing Phase 1a/1b trial of BTK degrader bexobrutideg (NX-5948) and provide a corporate update.
Presenters include investigator Alvaro Alencar, M.D., CEO Arthur T. Sands, M.D., Ph.D., and CMO Paula G. O’Connor, M.D.. The webcast and archived replay will be available in the Investors section of the Nurix website under Events and Presentations.
Nurix Therapeutics (Nasdaq: NRIX) announced that its president and CEO Arthur T. Sands, M.D., Ph.D. and CFO Hans van Houte will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:30 p.m. ET in New York City.
The session will be webcast live and accessible via a link in the company’s Investors section, and the archived webcast will be available for 30 days after the event.
Nurix Therapeutics (Nasdaq: NRIX) appointed Roger Dansey, M.D., to its board of directors on November 10, 2025. Dr. Dansey brings over two decades of oncology drug development and commercialization experience, including roles as Chief Development Officer and Chief Oncology Officer at Pfizer Oncology (Jan 2024–Mar 2025) and senior R&D leadership at Seagen, Merck, Gilead and Amgen.
The company said his expertise will support pivotal trials of its lead asset, bexobrutideg, in chronic lymphocytic leukemia and inform protein degradation programs for autoimmune diseases.
Nurix Therapeutics (Nasdaq: NRIX) presented translational data on Nov 7, 2025 from its ongoing Phase 1a study of oral CBL-B inhibitor NX-1607 at SITC 2025.
Key findings show dose-dependent pharmacology and target engagement (pHS1 modulation), peripheral T cell activation and proliferation correlated with stable disease versus progressive disease, and a case study in metastatic castration-resistant prostate cancer (5 prior therapies) showing stable disease with increased CD8+ TIL density and upregulated interferon and cytotoxic pathways. RNA sequencing showed dose-dependent enrichment of immune signaling pathways, linking systemic immune activation to tumor microenvironment remodeling.
Nurix Therapeutics (Nasdaq: NRIX) announced that updated clinical data from the NX-5948-301 Phase 1a/1b trial will be presented at the 67th ASH Annual Meeting, December 6–9, 2025 in Orlando.
Two company clinical presentations will feature: an oral presentation reporting new results in relapsed/refractory chronic lymphocytic leukemia (CLL) on Dec 6, 2025 at 9:45 a.m. ET, and a poster with updated Waldenström macroglobulinemia results on Dec 8, 2025 at 6:00 p.m. ET. In addition, a separate poster will present new mechanistic insights on BTK resistance (BTK A428D mutation) on Dec 6, 2025 at 5:30 p.m. ET.
The presenters named include Zulfa Omer, M.D. (CLL oral), Scott Huntington, M.D., MPH (Waldenström poster), and Quinlan Sievers, M.D., Ph.D. (BTK resistance poster).
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
